Product Name
GNPAT, siRNA
Full Product Name
GNPAT siRNA (Human)
Product Synonym Names
DAPAT; DHAPAT; Dihydroxyacetone phosphate acyltransferase; DAP-AT; DHAP-AT; Acyl-CoA:dihydroxyacetonephosphateacyltransferase; Glycerone-phosphate O-acyltransferase
Product Gene Name
GNPAT sirna
[Similar Products]
Research Use Only
For Research Use Only. Not for use in diagnostic procedures.
3D Structure
ModBase 3D Structure for O15228
Specificity
GNPAT siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
Purity/Purification
> 97%
Form/Format
Lyophilized powder
Quality Control
Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
Directions for Use
We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
Components
We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of human GNPAT gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
Preparation and Storage
Shipped at 4 degree C. Store at -20 degree C for one year.
Negative Control
siRNA Negative Control (Catalog# MBS8241404) is a non-targeting 21 nt siRNA recommended as a negative control for experiments using targeted siRNA transfection.
Other Notes
Small volumes of GNPAT sirna vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Related Product Information for
GNPAT sirna
siRNA to inhibit GNPAT expression using RNA interference
Applications Tested/Suitable for GNPAT sirna
RNA Interference (RNAi)
NCBI/Uniprot data below describe general gene information for GNPAT. It may not necessarily be applicable to this product.
NCBI Accession #
NP_055051.1
[Other Products]
NCBI GenBank Nucleotide #
NM_014236.3
[Other Products]
UniProt Primary Accession #
O15228
[Other Products]
UniProt Secondary Accession #
Q5TBH7; Q9BWC2; B4DNM9[Other Products]
UniProt Related Accession #
O15228[Other Products]
Molecular Weight
69,906 Da
NCBI Official Full Name
dihydroxyacetone phosphate acyltransferase
NCBI Official Synonym Full Names
glyceronephosphate O-acyltransferase
NCBI Official Symbol
GNPAT??[Similar Products]
NCBI Official Synonym Symbols
DAPAT; DAP-AT; DHAPAT
??[Similar Products]
NCBI Protein Information
dihydroxyacetone phosphate acyltransferase
UniProt Protein Name
Dihydroxyacetone phosphate acyltransferase
UniProt Synonym Protein Names
Acyl-CoA:dihydroxyacetonephosphateacyltransferase; Glycerone-phosphate O-acyltransferase
Protein Family
Dihydroxyacetone phosphate acyltransferase
UniProt Gene Name
GNPAT??[Similar Products]
UniProt Synonym Gene Names
DAPAT; DHAPAT; DAP-AT; DHAP-AT??[Similar Products]
UniProt Entry Name
GNPAT_HUMAN
NCBI Summary for GNPAT
This gene encodes an enzyme located in the peroxisomal membrane which is essential to the synthesis of ether phospholipids. Mutations in this gene are associated with rhizomelic chondrodysplasia punctata. [provided by RefSeq, Jul 2008]
UniProt Comments for GNPAT
GNPAT: Defects in GNPAT are the cause of rhizomelic chondrodysplasia punctata type 2 (RCDP2). RDCP2 is characterized by rhizomelic shortening of femur and humerus, vertebral disorders, cataract, cutaneous lesions and severe mental retardation. Belongs to the GPAT/DAPAT family.
Protein type: EC 2.3.1.42; Lipid Metabolism - glycerophospholipid; Transferase
Chromosomal Location of Human Ortholog: 1q42
Cellular Component: peroxisomal membrane; peroxisomal matrix; mitochondrion; membrane; peroxisome
Molecular Function: glycerone-phosphate O-acyltransferase activity; palmitoyl-CoA hydrolase activity; receptor binding
Biological Process: response to starvation; response to drug; synaptogenesis; phospholipid metabolic process; glycerophospholipid biosynthetic process; phosphatidic acid biosynthetic process; cerebellum morphogenesis; cellular lipid metabolic process; response to nutrient; ether lipid biosynthetic process; paranodal junction assembly
Disease: Rhizomelic Chondrodysplasia Punctata, Type 2
Research Articles on GNPAT
1. ACOX1 and GNPAT silencing up-regulated ceramide galactosyltransferase (UGT8) mRNA expression, and down-regulated UDP-glucoseceramide glucosyltransferase (UGCG).
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
